Specific Aim. Prostate cancer (PCA) is a molecularly heterogeneous disease with a varied clinical spectrum ranging from indolent to highly aggressive. One late manifestation of PCA is progression to a neuroendocrine phenotype, which is universally lethal with an average survival of less than one year. It is estimated that 30% of late stage PCA transforms to neuroendocrine prostate cancer (NEPC), and potentially selected for or accelerated by the use of androgen deprivation therapies. With the introduction of more potent hormonal therapy into the clinical arena (e.g., Abiraterone, MDV3100), the incidence of NEPC is expected to escalate. We have generated preliminary data from Whole Genome DNA and RNA Sequencing leading us to hypothesize that NEPC arises from adenocarcinoma (AdCa) and that telltale molecular events determine a progression from hormone na?ve AdCa to lethal NEPC. Therefore, we propose 3 Specific Aims to elucidate the key molecular drivers of NEPC.
Specific Aim 1 : Define Somatic Copy Number Alterations Associated with the Emergence of NEPC. The working hypothesis of this Aim is that there are recurrent somatic copy number alterations (SCNA) associated with NEPC detectable prior to the development of neuroendocrine de-differentiation. At the conclusion of this Aim, we will nominate up to 20 genes from SCNA loci that are recurrent in NEPC and less common in AdCa with transcriptional support suggesting that these are gain of function (oncogenes) or loss of function (tumor suppressor) genes.
Specific Aim 2 : Determine Spectrum of Mutations Observed in NEPC. The working hypothesis of this Aim is that there are specific driving mutations that characterize NEPC. At the end of this Aim, we anticipate that a subset of these mutations and rearrangements contribute to neuroendocrine de-differentiation. We anticipate nominating up to 20 mutations that will be appropriate for further molecular functional evaluation.
Specific Aim 3 Determine the Functional Activity of NEPC Genes. The working hypothesis of this Aim is that alterations in a subset of the genes nominated in Aims 1-2 are gain or loss of function mutations. At the conclusion of this Aim we will have nominated up to 5 functionally active genes that are present in NEPC and a subset of AdCa. We will immediately follow up on these genes using xenograft models as part of another funded grant (no animal experiments are proposed in this application). We believe that the proposed studies will allow us new insight into a highly aggressive form of PCA.
Prostate Cancer is the most common non-cutaneous cancer and the second leading cause of cancer death in American men with over 31,000 estimated death in 2010. Neuroendocrine prostate cancer, the focus of this study, is a well-defined subtype of prostate cancer that is universally lethal with an average survival of less than one year. Neuroendocrine differentiation is most commonly found in advanced stage prostate cancer and after exposure to androgen deprivation therapy, and is associated with a poor clinical outcome. It is estimated that at least 30% of late stage prostate cancer transform to, and potentially selected for or accelerated by the use of androgen deprivation therapies. With the introduction of more potent hormonal therapy into the clinical arena (e.g., Abiraterone, MDV3100), the incidence of Neuroendocrine prostate cancer is expected to escalate. There is currently no effective therapy for NEPC, and many patients are treated with platinum based chemotherapy (similar to small cell lung cancer). Despite a reported response rate of 50-60% to chemotherapy, most patients with NEPC progress within 6 months and survive less than one year. Neuroendocrine prostate cancer is a highly understudied type of cancer. This is due to clinical practices that do not harvest advanced prostate cancer except under special circumstances. Our proposed study has taken an ambitious approach to gather samples from around the world and use high throughput genome sequecning to help understand the molecular underpinnings of this lethal disease.
|Beltran, Himisha; Prandi, Davide; Mosquera, Juan Miguel et al. (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22:298-305|
|Pritchard, Colin C; Mateo, Joaquin; Walsh, Michael F et al. (2016) Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 375:443-53|
|Beltran, Himisha; Eng, Kenneth; Mosquera, Juan Miguel et al. (2015) Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. JAMA Oncol 1:466-74|
|Romanel, Alessandro; Gasi Tandefelt, Delila; Conteduca, Vincenza et al. (2015) Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med 7:312re10|
|Robinson, Dan; Van Allen, Eliezer M; Wu, Yi-Mi et al. (2015) Integrative clinical genomics of advanced prostate cancer. Cell 161:1215-28|
|Epstein, Jonathan I; Amin, Mahul B; Beltran, Himisha et al. (2014) Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol 38:756-67|
|Gao, Dong; Vela, Ian; Sboner, Andrea et al. (2014) Organoid cultures derived from patients with advanced prostate cancer. Cell 159:176-87|
|Carreira, Suzanne; Romanel, Alessandro; Goodall, Jane et al. (2014) Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 6:254ra125|
|Prandi, Davide; Baca, Sylvan C; Romanel, Alessandro et al. (2014) Unraveling the clonal hierarchy of somatic genomic aberrations. Genome Biol 15:439|
|Beltran, Himisha; Tomlins, Scott; Aparicio, Ana et al. (2014) Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res 20:2846-50|
Showing the most recent 10 out of 27 publications